What are advantages and shortfalls between Eylea and Vabysmo in treatment of

Eylea (aflibercept) advantages: It is licensed for treatment of neovascular (wet) age-related macular degeneration (nAMD), diabetic macular oedema (DMO), macular oedema secondary to retinal vein occlusion, and myopic choroidal neovascularisation in adults SmPC Eylea,SmPC Eylea,SmPC Eylea. Its dosing regimens have been studied extensively, including fixed intervals, treat-and-extend, and as-needed schedules, showing comparable efficacy and safety profiles SmPC Eylea. Eylea treatment can lead to significant improvements in vision, with clinical studies showing a mean gain of over 13 letters in vision for DMO with manageable injection frequencies SmPC Eylea. The safety profile is well characterized and comparable across studies with few serious ocular or systemic adverse events SmPC Eylea. It allows flexible dosing intervals, which can reduce treatment burden compared to monthly injections SmPC Eylea.

Eylea disadvantages: Requires intravitreal injections, which can be uncomfortable and require specialist administration NICE CKS. Regular monitoring and possibly long-term treatment are required, with injections potentially continuing beyond 2 years NICE CKS,SmPC Eylea. Potential risks include ocular and systemic adverse events typical of anti-VEGF agents, although these are comparable to other treatments SmPC Eylea.

Vabysmo (faricimab) advantages and disadvantages: The provided context does not include specific information on Vabysmo, its advantages, or disadvantages, nor its comparison to Eylea in degenerative macular disease treatment. Therefore, no direct statements can be made from the supplied evidence about Vabysmo.